This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lappin, T. Search for Related Content PubMed PubMed Citation Articles by Lappin, T.

The Cellular Biology of Erythropoietin Receptors

Queen’s University Belfast, Belfast City Hospital, Belfast, Northern Ireland

Correspondence: Terry Lappin, Ph.D., Queen’s University Belfast, Belfast City Hospital, U Floor, Tower Block, Lisburn Road, Belfast BT9 7AB, Northern Ireland. Telephone: 44-0-2890-329241, ext 2013; Fax: 44-0-2890-263927; e-mail: t.lappin{at}qub.ac.uk

Long thought to act only as a hormone that was the primary regulator of red blood cell production, erythropoietin is now known to have a whole spectrum of activity. Organs such as the brain, ovary, oviduct, uterus, and testis have erythropoietin receptors. Because erythropoietin receptors exist in the paracrine and autocrine systems, as well as the hormonal system, the beneficial effects of administering human erythropoietin are likely to extend beyond its effect in raising hematocrit. It may even be possible in the future to use the receptors to target a drug to a tumor without damaging the surrounding tissue.

Key Words. Erythropoietin receptors • Recombinant erythropoietin • Neoplasms

This article has been cited by other articles:

				A. M. Chabowska, M. Sulkowska, A. Chabowski, A. Wincewicz, M. Koda, and S. Sulkowski Erythropoietin and Erythropoietin Receptor in Colorectal Cancer International Journal of Surgical Pathology, July 1, 2008; 16(3): 269 - 276. [Abstract] [PDF]

				M. S. Lee, J. S. Lee, and J. Y. Lee Prevention of Erythropoietin-Associated Hypertension Hypertension, August 1, 2007; 50(2): 439 - 445. [Abstract] [Full Text] [PDF]

				L. Zhong, J. Bradley, W. Schubert, E. Ahmed, A. P. Adamis, D. T. Shima, G. S. Robinson, and Y.-S. Ng Erythropoietin Promotes Survival of Retinal Ganglion Cells in DBA/2J Glaucoma Mice Invest. Ophthalmol. Vis. Sci., March 1, 2007; 48(3): 1212 - 1218. [Abstract] [Full Text] [PDF]

				J. Y. Lee Purification of Biologically Active Human Erythropoietin-Binding Protein and Detection of its Binding Sites Ann. Clin. Lab. Sci., January 1, 2007; 37(1): 63 - 70. [Abstract] [Full Text] [PDF]

				K. R. LaMontagne, J. Butler, D. J. Marshall, J. Tullai, Z. Gechtman, C. Hall, A. Meshaw, and F. X. Farrell Recombinant epoetins do not stimulate tumor growth in erythropoietin receptor-positive breast carcinoma models. Mol. Cancer Ther., February 1, 2006; 5(2): 347 - 355. [Abstract] [Full Text] [PDF]

				F. Farrell and A. Lee The Erythropoietin Receptor and Its Expression in Tumor Cells and Other Tissues Oncologist, November 1, 2004; 9(suppl_5): 18 - 30. [Abstract] [Full Text] [PDF]

				P. A. Daly Introduction: All Ireland Fatigue Coalition Oncologist, February 1, 2003; 8(90001): 1 - 2. [Abstract] [Full Text] [PDF]